Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Lu Peng, Chief Medical Officer of Pharvaris N.V., reported an exercise-and-sale sequence under a Rule 10b5-1 trading plan. Peng exercised options to acquire 18,733 shares of common stock at $2.59 per share and sold the same number of shares in open-market transactions at weighted average prices around $30 on April 29–30, 2026.
Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock and 219,474 stock options from the referenced grant, which remains outstanding until February 3, 2030.
Pharvaris N.V. director Johannes Schikan reported open-market sales of 7,100 shares of Common Stock in two transactions. He sold 7,000 shares on April 22, 2026 at $30.0541 per share and 100 shares on April 23, 2026 at $30.03 per share, under a pre-planned Rule 10b5-1 trading plan. Following these sales, he directly holds 388,067 Pharvaris shares.
Pharvaris N.V. Chief Early Development officer Anne Lesage reported a combination of stock option exercises and share sales in Pharvaris common stock. On April 22–23, 2026, she exercised 7,600 stock options and sold 14,700 common shares in open-market transactions at prices around $30 per share, as part of a Rule 10b5-1 trading plan.
Following these transactions, Lesage holds 56,450 Pharvaris shares directly and 156,869 shares indirectly through GrayMatters Consulting B.V. The exercised options carried strike prices of $8.05 and $2.59 and were originally subject to multi-year vesting schedules.
Pharvaris N.V. Chief Medical Officer Lu Peng executed a small, pre-planned option exercise-and-sell transaction under a Rule 10b5-1 trading plan. On April 22–23, 2026, Peng exercised options to acquire 7,101 shares of common stock at $2.59 per share and sold the same 7,101 shares in open-market transactions around $30 per share.
After these trades, Peng directly holds 66,083 shares of common stock and 106,207 stock options expiring in 2030. The filing characterizes the activity as a scheduled transaction pursuant to a Rule 10b5-1 trading plan, indicating it was arranged in advance rather than timed opportunistically.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a routine tax-related share withholding. On April 16, 2026, 226 common shares were disposed of at a fair market value of $28.78 per share to satisfy tax withholding obligations from restricted stock units that vested on April 11 and April 12, 2026. After this non‑market transaction, Lu Peng directly held 66,083 common shares.
Pharvaris N.V. Chief Executive Officer Berndt Modig reported a small open-market sale of company stock. On April 16, 2026, he sold 2,292 shares of Pharvaris common stock at a weighted average price of $28.6032 per share in a series of trades executed under a Rule 10b5-1 trading plan. These sales involved shares that include stock previously acquired upon vesting of restricted stock units. After the sale, he directly owns 139,792 shares of common stock and also has an indirect holding of 950,000 shares through Schoodic Management BV, an entity he controls, indicating he retains a substantial overall stake in the company.